Q4 2025 was either the inflection or the warning — both essays cite the same chart.

• The bull's chart. Quarterly operating margin marched from −34% (Q4 2024) to −4.1%, −5.1%, −8.4%, and −0.9% (Q4 2025) on revenue reaccelerating to +18% YoY. Four straight quarters compressing toward a breakeven line that hasn't been crossed since 2019; FY2025 closed non-GAAP positive at $1.2M, the first time since IPO.
• The bear's chart. Selling & marketing — the only line item that moves operating margin in this model — printed at 64.8% of revenue in Q4 2025, up from 60.1% in Q4 2024. The single number the FY2026 thesis depends on moved against the thesis on the most recent print, in the most important traffic quarter of the year.
• One print resolves it. Q1 2026 results land mid-May. Below 60% S&M and at-or-above-zero non-GAAP operating margin, and the four-quarter compression survives a non-Double-11 quarter. Above 60%, and Q4 was a Double-11 sugar high.

World-class gross margin, sub-scale operating margin, fortress balance sheet — the gap between the lines is the entire investment case.

Mix shift from color cosmetics to premium skincare drove gross margin from 64% to 78% in seven years; selling & marketing intensity (still 63% of revenue) is the only thing keeping operating margin negative. With $150M of cash, zero financial debt, and a four-quarter trajectory toward breakeven, the equity is being priced as if breakeven won't arrive — net of cash, the operating brand portfolio is worth roughly nothing.

No longer a Perfect Diary stub — color is a managed-decline cash unit; skincare is now most of the company.

Then. The 2020 IPO sold a 'data-driven' mass color cosmetics story — Perfect Diary on Tmall, KOL-and-livestream moat, 32M DTC customers as the headline metric. The Tmall traffic engine compounded into a $25B market cap by February 2021.

The break. Revenue collapsed 35% in FY2022 as Douyin replaced Tmall as China's dominant beauty traffic source — at roughly twice the cost per acquired customer. The 32M-customer metric vanished from disclosures; KOL/MCN was quietly dropped from the moat description.

Now. Skincare hit 53% of FY2025 revenue (61% in Q4) on +63% growth; color cosmetics declined 9% in Q4 and is being managed for cash. Acquired premium brands — Galénic, Eve Lom, DR.WU — are the engine. Non-GAAP profitability arrived 14 quarters after the pivot was announced.

Founder controls 91% of the vote, just wired personal capital in at the bottom — and is also the related-party counterparty.

• The voting lock. CEO Jinfeng Huang holds 35% of the economics and 91% of the votes through 600M Class B shares carrying 20 votes each. Hillhouse and ZhenFund together own 28% of the equity but control under 5% of the vote. There is no contestable board outcome.
• The convertible. March 2026 — Huang personally subscribed to ~half of a $120M convertible alongside Trustar Capital. 1.5% coupon, 20% conversion premium, warrants on top. Bull reads 'I believe'; bear reads cheap related-party paper minorities can't access, with proceeds earmarked for the same premium-skincare-M&A mandate that produced $108M of Eve Lom impairments.
• Related-party purchases doubled. Inventory and services bought from companies under Huang's control: $20M (FY22) → $41M (FY24), now 8.3% of revenue. Pricing methodology and counterparty breakdown not disclosed.

Three dated events in the next four months settle the central operating question.

• April 30 — FY2025 20-F. Audited financials, Eve Lom carrying-value review, related-party-transaction footnote, class-action contingency. The first chance to spot a third Eve Lom goodwill writedown.
• May 15 — Q1 2026 print. Management guided $137M–$154M revenue (+15% to +30% YoY). The number that matters is S&M as percent of revenue: below 60% confirms the four-quarter trajectory; above 60% says Q4 was Double-11 noise.
• By June 30 — Trustar second tranche (~$60M) closes. Whether the second tranche actually funds — and whether management has earmarked a specific acquisition target — tells you whether the war chest is for a sub-$30M tuck-in or another premium-brand bet on the Eve Lom pattern.